GO847

GO847 (1×10^-11-1×10^-6 M) potently inhibits CK2 enzymatic activity in vitro with an IC₅₀ of 40.2 nM^[1].
GO847 (0-20 μM; 48 h) dose-dependently inhibits the growth of mouse AML C1498 cells (IC₅₀ = 5.1 μM) and human AML THP-1 cells (IC₅₀ = 1.7 μM) after 48 h of treatment^[1].
GO847 (0.9-8 μM; 24 h) dose-dependently inhibits cellular CK2 activity in mouse AML C1498 cells and human AML THP-1 cells after 24 h of treatment, reducing phosphorylation of CK2 substrates including AKT1^(S129)[1].
GO847 (5 μM; 24 h) impairs mitochondrial metabolic flexibility in mouse AML C1498 cells after 24 h of treatment, reducing spare respiratory capacity and abolishing glycolytic compensation in response to mitochondrial inhibition^[1].
GO847 increases ATP levels, elevates mitochondrial membrane potential, and promotes excessive mitochondrial ROS production in mouse AML C1498 cells after 24 h of treatment with 5 μM GO847^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.